A New Biologic Model Predicts Survival in Diffuse Large B-Cell Lymphoma

Prognostic scores based on immunohistochemical markers correlate strongly with overall and event-free survival.

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous subtype of non-Hodgkin lymphoma in which better or poorer outcomes are associated with specific tumor-cell and tumor-microenvironment characteristics. However, identifying such biomarkers has required the use of molecular techniques that are not readily available in routine clinical practice.

Now, investigators have developed a biologic prognostic model (BPM) that uses widely available immunohistochemistry methods to predict survival of DLBCL patients. The study involved 199 patients (125 in a training group and 74 in a validation group) with newly diagnosed de novo disease who were treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) o…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee